Literature DB >> 25824652

The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy - the MD Anderson Cancer Center experience.

Philip A Thompson1, Uri Rozovski1, Michael J Keating1, Francesco Stingo2, Susan C Smith1, William G Wierda1, Lorenzo Falchi1, Susan M O'Brien1, Zeev Estrov1, Jan A Burger1, Alessandra Ferrajoli1.   

Abstract

Entities:  

Keywords:  CD20 monoclonal antibodies; chronic lymphocytic leukaemia; lenalidomide; relapsed/refractory

Year:  2015        PMID： 25824652      PMCID： PMC4589497          DOI： 10.1111/bjh.13377

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

Authors:  Christine I Chen; P Leif Bergsagel; Harminder Paul; Wei Xu; Anthea Lau; Nimisha Dave; Vishal Kukreti; Ellen Wei; Chungyee Leung-Hagesteijn; Zhi Hua Li; Joseph Brandwein; Mariela Pantoja; James Johnston; Spencer Gibson; Tiffany Hernandez; David Spaner; Suzanne Trudel
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

2.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

Authors:  Valentin Goede; Kirsten Fischer; Raymonde Busch; Anja Engelke; Barbara Eichhorst; Clemens M Wendtner; Tatiana Chagorova; Javier de la Serna; Marie-Sarah Dilhuydy; Thomas Illmer; Stephen Opat; Carolyn J Owen; Olga Samoylova; Karl-Anton Kreuzer; Stephan Stilgenbauer; Hartmut Döhner; Anton W Langerak; Matthias Ritgen; Michael Kneba; Elina Asikanius; Kathryn Humphrey; Michael Wenger; Michael Hallek
Journal:  N Engl J Med       Date:  2014-01-08       Impact factor: 91.245

3.  Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia.

Authors:  Xavier C Badoux; Michael J Keating; Sijin Wen; Bang-Ning Lee; Mariela Sivina; James Reuben; William G Wierda; Susan M O'Brien; Stefan Faderl; Steven M Kornblau; Jan A Burger; Alessandra Ferrajoli
Journal:  Blood       Date:  2011-07-01       Impact factor: 22.113

4.  Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.

Authors:  Paolo Strati; Michael J Keating; William G Wierda; Xavier C Badoux; Steliana Calin; James M Reuben; Susan O'Brien; Steven M Kornblau; Hagop M Kantarjian; Hui Gao; Alessandra Ferrajoli
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

5.  Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.

Authors:  Xavier C Badoux; Michael J Keating; Sijin Wen; William G Wierda; Susan M O'Brien; Stefan Faderl; Rachel Sargent; Jan A Burger; Alessandra Ferrajoli
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

6.  Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.

Authors:  Yibin Yang; Arthur L Shaffer; N C Tolga Emre; Michele Ceribelli; Meili Zhang; George Wright; Wenming Xiao; John Powell; John Platig; Holger Kohlhammer; Ryan M Young; Hong Zhao; Yandan Yang; Weihong Xu; Joseph J Buggy; Sriram Balasubramanian; Lesley A Mathews; Paul Shinn; Rajarshi Guha; Marc Ferrer; Craig Thomas; Thomas A Waldmann; Louis M Staudt
Journal:  Cancer Cell       Date:  2012-06-12       Impact factor: 31.743

7.  Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Authors:  Asher Chanan-Khan; Kena C Miller; Laurie Musial; David Lawrence; Swaminathan Padmanabhan; Kenichi Takeshita; Carl W Porter; David W Goodrich; Zale P Bernstein; Paul Wallace; David Spaner; Alice Mohr; Catriona Byrne; Francisco Hernandez-Ilizaliturri; Cynthia Chrystal; Petr Starostik; Myron S Czuczman
Journal:  J Clin Oncol       Date:  2006-11-06       Impact factor: 44.544

8.  lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.

Authors:  Lei Wu; Mary Adams; Troy Carter; Roger Chen; George Muller; David Stirling; Peter Schafer; J Blake Bartlett
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

9.  Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli; Bang-Ning Lee; Ellen J Schlette; Susan M O'Brien; Hui Gao; Sijin Wen; William G Wierda; Zeev Estrov; Stefan Faderl; Evan N Cohen; Changping Li; James M Reuben; Michael J Keating
Journal:  Blood       Date:  2008-03-11       Impact factor: 22.113
  9 in total
  2 in total

1.  Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL.

Authors:  Paolo Strati; Koichi Takahashi; Christine B Peterson; Michael J Keating; Philip A Thompson; Naval G Daver; Nitin Jain; Jan A Burger; Zeev Estrov; Susan M O'Brien; Hagop M Kantarjian; William G Wierda; P Andrew Futreal; Alessandra Ferrajoli
Journal:  Blood Adv       Date:  2019-05-14

2.  Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia.

Authors:  Arnon P Kater; Marinus H J van Oers; Yvette van Norden; Lina van der Straten; Julia Driessen; Ward F M Posthuma; Martin Schipperus; Martine E D Chamuleau; Marcel Nijland; Jeanette K Doorduijn; Michel Van Gelder; Mels Hoogendoorn; Francien De Croon; Shulamiet Wittebol; J Martijn Kerst; Erik W A Marijt; Reinier A P Raymakers; Martijn R Schaafsma; Johan A Dobber; Sabina Kersting; Mark-David Levin
Journal:  Haematologica       Date:  2018-08-16       Impact factor: 9.941
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.